VolitionRX Earnings Call: Breakthrough Science, Cash Burn Risk

VolitionRX Ltd. ((VNRX)) has held its Q1 earnings call. Read on for the main highlights of the call.

VolitionRX’s latest earnings call balanced clear scientific momentum with financial caution. Management highlighted strong revenue growth and a bolstered cash position, but also stressed that much of the top-line jump was timing-related while cash burn remains significant. Technical wins across Vet, NETs, and Capture-Seq platforms energized the narrative, yet execution and validation risks still loom.

Revenue growth flattered by deferred recognition

VolitionRX reported Q1 FY2026 revenue of about $1.0 million, up roughly 300% from $0.2 million a year earlier. The surge was driven mainly by a $0.7 million deferred revenue recognition tied to the Nu.Q Vet Heska agreement, underscoring that much of the growth came from accounting catch-up rather than visibly scaled recurring sales.

Cash position strengthened by financing and grants

Cash and equivalents climbed to approximately $3.1 million from $1.1 million at the end of December, aided by external funding. The company drew about $5.4 million net from its at-the-market facility, $1.9 million from a convertible note, and around $1.0 million in non-dilutive funding, with a further $0.9 million expected in staged payments.

Operating loss narrows despite higher expenses

Operating loss improved by about 3% year-on-year even as operating expenses rose. Management cited cost-control efforts and revenue recognition adjustments as the key drivers, suggesting some early progress in managing the P&L while still investing heavily in R&D and commercialization.

Nu.Q Vet hits automation and feline assay milestones

The company completed validation of its chemiluminescent Nu.Q Vet test with Fujifilm Vet Systems in Japan, enabling full central-lab automation for the first time. A feline lymphoma prototype assay showed 86% detection at 97% specificity in submitted data, and its anticipated publication is expected to unlock a sizable milestone payment under the Heska deal.

Nu.Q NETs gains academic backing and POC potential

A Mayo Clinic trauma study with 674 subjects showed dramatic nucleosome elevations, with H3.1 levels jumping from 22.3 ng/mL in healthy volunteers to 359.7 in trauma and 828.4 in VTE cases. Volition also demonstrated finger-prick lateral-flow nucleosome detection, a breakthrough that could underpin point-of-care tests for trauma and sepsis in low-resource settings.

Capture-Seq shows high-purity ctDNA and early detection

Volition unveiled a two-step CTCF Capture-Seq method producing sequencing sets with over 99% tumor-derived DNA purity. In a blinded cohort of 81 subjects, the platform detected more than 95% of Stage 1 and 2 colorectal and lung cancers, a compelling early signal that has already attracted strong inbound interest and patent activity.

Nu.Q Discover and webshop broaden commercial reach

The Nu.Q Discover business expanded with a nonexclusive partnership with MBL in Japan, helping push the collaborator base to roughly 100 clients worldwide. The launch of an rNuQ webshop, offering ISO 13485-grade recombinant nucleosomes, creates a new revenue stream and positions Volition as a tools supplier to researchers and diagnostic developers.

Regulatory and reimbursement progress for Nu.Q Lung

Recruitment for the Nu.Q Lung Ulysses MAP validation study has been completed, with IVDR documentation said to be ahead of schedule. Reimbursement pre-submission work with Hospices Civils de Lyon is under way, and the company is targeting potential clinical routine use of its lung test in France later this year, subject to payor and regulatory outcomes.

Revenue volatility and lack of 2026 guidance

Management reiterated that revenues remain lumpy and difficult to forecast, reflecting milestone timing and deferred revenue effects. With no formal 2026 revenue guidance offered, investors are left with strong percentage growth headlines but limited visibility into when more stable, recurring diagnostic revenue might emerge.

Rising operating costs and ongoing cash burn

Operating expenses increased to $6.3 million from $5.8 million, driven by severance and elevated R&D spend. Net cash used in operations rose to $5.3 million from $4.3 million, underlining continued cash burn and reinforcing the company’s dependence on future financings, grants, and milestone receipts to sustain its development plans.

Dependence on external funding and milestones

Despite the quarter’s improved cash balance, Volition remains reliant on equity facilities, convertible debt, and non-dilutive grants. Key expected milestones, such as the sizable feline assay payment, have yet to be realized, creating timing risk that could pressure liquidity if scientific or publication timelines slip.

Early-stage data still needs broader validation

Many of Volition’s strongest claims—from Capture-Seq’s purity and early-stage cancer detection to Nu.Q Vet’s feline performance and NETs-based sepsis applications—are backed by relatively early datasets. Management acknowledged that larger cohorts, peer-reviewed publications, and regulatory and reimbursement approvals are still needed to de-risk commercialization.

Partner revenues remain limited and unpredictable

Existing collaborations with major diagnostics players are largely in technical validation or pilot phases, and management did not highlight meaningful recurring revenue from these relationships. That leaves the timing and magnitude of partner-driven sales uncertain, even as scientific collaborations expand and generate promising data.

Forward-looking outlook centered on milestones, not guidance

Volition refrained from issuing formal 2026 revenue guidance, instead pointing investors to upcoming operational milestones and funding tranches. Key near-term events include the first DETECSEPS patient enrollment expected in Q3, potential French reimbursement progress later this year, the awaiting feline publication-linked payment, and continued cost-reduction efforts to manage burn.

VolitionRX’s call painted a picture of a company rich in scientific innovation but still climbing the commercialization curve. Investors get a story of rapid technical progress, expanding collaborations, and a shored-up balance sheet, offset by revenue lumpiness, rising costs, and execution risk. The next year’s milestones will be critical in proving that these breakthroughs can translate into durable, predictable cash flows.